We are live on
!
Find out more
Aberdeen Group Portfolio holdings
AUM
$61.9B
1-Year Est. Return
29.81%
This Fund
S&P 500
This Quarter
Est. Return
+5.07%
1 Year Est. Return
+29.81%
3 Year Est. Return
+93.17%
5 Year Est. Return
+119.65%
10 Year Est. Return
–
AUM
$64.6B
AUM Growth
+$1.37B
(+2.2%)
Cap. Flow
-$686M
Cap. Flow
% of AUM
-1.06%
Top 10 Holdings %
Top 10 Hldgs %
38.17%
Holding
995
New
43
Increased
362
Reduced
491
Closed
59
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Nu Holdings
NU
|
+$36.3M |
| 2 |
SCHW
Charles Schwab
SCHW
|
+$36.1M |
| 3 |
Ascendis Pharma A/S
ASND
|
+$35.6M |
| 4 |
Danaher
DHR
|
+$30.5M |
| 5 |
uniQure
QURE
|
+$28.5M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Eli Lilly
LLY
|
+$93.5M |
| 2 |
Mercado Libre
MELI
|
+$86M |
| 3 |
Microsoft
MSFT
|
+$62.9M |
| 4 |
Apple
AAPL
|
+$55.6M |
| 5 |
BioMarin Pharmaceuticals
BMRN
|
+$48.9M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Technology | 32.59% |
| 2 | Healthcare | 13.39% |
| 3 | Consumer Discretionary | 11.41% |
| 4 | Communication Services | 11.25% |
| 5 | Financials | 10.55% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
751
Sixth Street Specialty
TSLX
$1.67B
| $2.68M | ﹤0.01% |
123,237
| – | – |
|
752
First Industrial Realty Trust
FR
$8.66B
| $2.65M | ﹤0.01% |
46,272
+2,467
| +6% | +$138K |
|
753
Global Net Lease
GNL
$1.87B
| $2.65M | ﹤0.01% |
308,042
+66,657
| +28% | +$534K |
|
754
Ares Capital
ARCC
$13.4B
| $2.64M | ﹤0.01% |
130,322
| – | – |
|
755
Park Hotels & Resorts
PK
$3.08B
| $2.54M | ﹤0.01% |
243,231
+48,489
| +25% | +$519K |
|
756
Blue Owl Capital
OBDC
$5.35B
| $2.51M | ﹤0.01% |
202,091
| – | – |
|
757
Annaly Capital Management
NLY
$17.3B
| $2.5M | ﹤0.01% |
111,907
+26,489
| +31% | +$577K |
|
|
HSAI
758
Hesai Group
HSAI
$2.57B
| $2.45M | ﹤0.01% |
109,582
-1,256,158
| -92% | -$27.5M |
|
759
Essential Properties Realty Trust
EPRT
$6.92B
| $2.45M | ﹤0.01% |
82,726
+3,423
| +4% | +$104K |
|
760
Grab
GRAB
$13.7B
| $2.39M | ﹤0.01% |
479,019
| – | – |
|
761
Coca-Cola Europacific Partners
CCEP
$49.1B
| $2.37M | ﹤0.01% |
26,157
-3,577
| -12% | -$323K |
|
762
Viatris
VTRS
$20.8B
| $2.35M | ﹤0.01% |
189,098
-21,987
| -10% | -$237K |
|
763
Huazhu Hotels Group
HTHT
$13.3B
| $2.35M | ﹤0.01% |
50,017
-377
| -0.7% | -$16.3K |
|
764
Zillow
ZG
$7.85B
| $2.32M | ﹤0.01% |
34,032
+52
| +0.2% | +$3.66K |
|
|
MPT
765
Medical Properties Trust
MPT
$2.84B
| $2.32M | ﹤0.01% |
464,296
+2,145
| +0.5% | +$11.2K |
|
766
Terreno Realty
TRNO
$7.58B
| $2.3M | ﹤0.01% |
39,135
-117,311
| -75% | -$7.06M |
|
|
ORKA
767
Oruka Therapeutics
ORKA
$5.31B
| $2.29M | ﹤0.01% |
75,680
| – | – |
|
768
Ionis Pharmaceuticals
IONS
$8.93B
| $2.29M | ﹤0.01% |
28,926
-58,998
| -67% | -$4.44M |
|
|
DQ
769
Daqo New Energy
DQ
$810M
| $2.26M | ﹤0.01% |
76,557
-11,034
| -13% | -$337K |
|
770
Caribou Biosciences
CRBU
$146M
| $2.21M | ﹤0.01% |
1,388,905
| – | – |
|
771
Procept Biorobotics
PRCT
$1.02B
| $2.18M | ﹤0.01% |
69,142
+20,023
| +41% | +$664K |
|
772
Vornado Realty Trust
VNO
$7.65B
| $2.12M | ﹤0.01% |
63,762
-7,467
| -10% | -$273K |
|
|
CYBR
773
DELISTED
CyberArk
CYBR
| $2.12M | ﹤0.01% |
4,744
-1,458
| -24% | -$702K |
|
774
Ryman Hospitality Properties
RHP
$8.56B
| $2.09M | ﹤0.01% |
22,105
+1,280
| +6% | +$118K |
|
775
Iovance Biotherapeutics
IOVA
$2.04B
| $2.07M | ﹤0.01% |
759,522
+152,312
| +25% | +$352K |
|
Similar funds
Aberdeen Group's Q4 2025 Portfolio in Review
As of Q4 2025, Aberdeen Group held 995 positions worth $64.6B, up 2.2% from $63.2B the previous quarter. Its ten largest holdings account for 38% of the portfolio.
Aberdeen Group's Q4 2025 filing shows 43 new, 362 increased, 491 reduced and 59 closed positions. Its largest new stake was Praxis Precision Medicines: 134,992 shares worth $39.8M. The largest sale was Eli Lilly, an estimated $93.5M.
By sector, the portfolio is most concentrated in Technology at 33% of assets, down from 33% a quarter earlier, followed by Healthcare and Consumer Discretionary.
- Aberdeen Group's largest Q4 2025 buy was Praxis Precision Medicines: 134,992 shares worth $39.8M.
- Aberdeen Group added most to Nu Holdings in Q4 2025, an estimated $36.3M increase.
- Aberdeen Group's biggest Q4 2025 reduction was Eli Lilly, cutting an estimated $93.5M.
- Aberdeen Group fully exited BioMarin Pharmaceuticals in Q4 2025, selling an estimated $48.9M.
- Aberdeen Group's ten largest holdings make up 38% of its $64.6B portfolio in Q4 2025.
- Aberdeen Group opened 43 new positions and closed 59 in Q4 2025.
- Aberdeen Group's portfolio value rose 2.2% quarter-over-quarter to $64.6B.
Based on Aberdeen Group's 13F filing for Q4 2025, filed 16 Jan 2026.